Top

International Journal of Clinical Oncology

Published in:

01-08-2015 | Original Article

Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations

Authors: Toshihiko Iuchi, Masato Shingyoji, Meiji Itakura, Sana Yokoi, Yasumitsu Moriya, Hajime Tamura, Yasushi Yoshida, Hironori Ashinuma, Koichiro Kawasaki, Yuzo Hasegawa, Tsukasa Sakaida, Toshihiko Iizasa

Published in: International Journal of Clinical Oncology | Issue 4/2015

Abstract

Background

The brain is a frequent site of metastases from non-small-cell lung cancer (NSCLC). We analyzed the frequency of brain metastases (BMs) from NSCLC in the era of magnetic resonance images, and evaluated the correlation between epidermal growth factor receptor (EGFR) mutations and BMs among East Asian patients.

Methods

Frequency, number, and size of BMs, and survival of 1,127 NSCLC patients were retrospectively reviewed. Mutation status of EGFR was evaluated in all cases, and its association with BMs was statistically evaluated.

Results

EGFR mutations were found for 331 cases (29.4 %). BM was the cause of primary symptoms for 52 patients (4.6 %), and found before initiation of treatment for 102 other patients (9.1 %); In addition to these 154 patients, 107 patients (9.5 %) developed BMs, giving a total of 261 patients (23.2 %) who developed BMs from 1,127 with NSCLC. BM frequency was higher among EGFR-mutated cases (31.4 %) than EGFR-wild cases (19.7 %; odds ratio: 1.86; 95 % confidence interval (CI) 1.39–2.49; P < 0.001). BMs from EGFR-mutated NSCLC were small, but often became disseminated. EGFR mutations accounted for 39.9 % of BMs, but patient survival after BMs was significantly longer for EGFR-mutated cases than for EGFR-wild cases (hazard ratio: 2.23; 95 % CI 1.62–3.10; P < 0.001).

Conclusions

Patients with EGFR-mutated NSCLC were more likely to develop BMs, but apparently also survived longer after BMs.

Komaki R, Cox JD, Stark R (1983) Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: correlation with survival. Int J Radiat Oncol Biol Phys 9:1467–1470PubMedCrossRef

Sørensen JB, Hansen HH, Hansen M et al (1988) Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6:1474–1480PubMed

Auerbach O, Garfinkel L, Parks VR (1975) Histologic type of lung cancer in relation to smoking habits, year of diagnosis and sites of metastases. Chest 67:382–387PubMedCrossRef

Stenbygaard LE, Sørensen JB, Olsen JE (1995) Metastatic pattern in adenocarcinoma of the lung. An autopsy study from a cohort of 137 consecutive patients with complete resection. J Thorac Cardiovasc Surg 110:1130–1135PubMedCrossRef

Nichols L, Saunders R, Knollmann FD (2012) Causes of death of patients with lung cancer. Arch Pathol Lab Med 136:1552–1557PubMedCrossRef

Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257–262PubMedCrossRef

Shingyoij M, Kageyama H, Sakaida T et al (2011) Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol 6:1215–1220CrossRef

Suzuki K, Yamamoto M, Hasegawa Y et al (2004) Magnetic resonance imaging and computed tomography in the diagnoses of brain metastases of lung cancer. Lung Cancer 46:357–360PubMedCrossRef

Bauml J, Mick R, Zhang Y et al (2013) Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer 81:347–353PubMedCentralPubMedCrossRef

10.

Choi YL, Sun JM, Cho J et al (2013) EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One 8:e56011PubMedCentralPubMedCrossRef

11.

Calvo E, Baselga J (2006) Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 24:2158–2163PubMedCrossRef

12.

Nishie K, Kawaguchi T, Tamiya A et al (2012) Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol 7:1722–1727PubMedCrossRef

13.

Arrieta O, Cardona AF, Federico Bramuglia G et al (2011) Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol 6:1955–1959PubMedCrossRef

14.

Cote ML, Haddad R, Edwards DJ et al (2011) Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol 6:627–630PubMedCentralPubMedCrossRef

15.

Xu J, He J, Yang H et al (2011) Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer 10:63–69

16.

Reinersman JM, Johnson ML, Riely GJ et al (2011) Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 6:28–31PubMedCentralPubMedCrossRef

17.

Leidner RS, Fu P, Clifford B et al (2009) Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol 27:5620–5626PubMedCentralPubMedCrossRef

18.

Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339–346PubMedCrossRef

19.

Na II, Kim HR, Lee JK et al (2012) Epidermal growth factor receptor mutations in female patients with postoperative recurrent non-small-cell lung cancer. J Cancer Res Ther 8:373–378PubMedCrossRef

20.

Doval DC, Azam S, Batra U et al (2013) Epidermal growth factor receptor mutation in lung adenocarcinoma in India: a single center study. J Carcinog 12:12PubMedCentralPubMedCrossRef

21.

Matsumoto S, Takahashi K, Iwakawa R et al (2006) Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 119:1491–1494PubMedCrossRef

22.

Gow CH, Chang YL, Hsu YC et al (2009) Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 20:696–702PubMedCrossRef

23.

Hsiao SH, Lin HC, Chou YT et al (2013) Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients. Lung Cancer 81:455–461PubMedCrossRef

24.

Sun M, Behrens C, Feng L et al (2009) HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 15:4829–4837PubMedCentralPubMedCrossRef

25.

Villalva C, Duranton-Tanneur V, Guilloteau K et al (2013) EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. Cancer Med 2:296–304PubMedCentralPubMedCrossRef

26.

Welsh JW, Komaki R, Amini A et al (2013) Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31:895–902PubMedCentralPubMedCrossRef

27.

Breindel JL, Haskins JW, Cowell EP et al (2013) EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res 73:5053–5065PubMedCentralPubMedCrossRef

28.

Iuchi T, Shingyoji M, Sakaida T et al (2013) Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82:282–287PubMedCrossRef

29.

Lee HL, Chung TS, Ting LL et al (2012) EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol 7:181PubMedCentralPubMedCrossRef

Title: Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations
Authors: Toshihiko Iuchi
Masato Shingyoji
Meiji Itakura
Sana Yokoi
Yasumitsu Moriya
Hajime Tamura
Yasushi Yoshida
Hironori Ashinuma
Koichiro Kawasaki
Yuzo Hasegawa
Tsukasa Sakaida
Toshihiko Iizasa
Publication date: 01-08-2015
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-014-0760-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2015

Treatment modalities for Māori and New Zealand European men with localised prostate cancer

Prognostic implications of receptor discordance between primary and recurrent breast cancer

Erratum to: Outcomes of abdominal radical trachelectomy: results of a multicenter prospective cohort study in a Tohoku Gynecologic Cancer Unit

Expression and role of V1A subunit of V-ATPases in gastric cancer cells

Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer

Outcomes of abdominal radical trachelectomy: results of a multicenter prospective cohort study in a Tohoku Gynecologic Cancer Unit

Keynote webinar | Spotlight on antibody–drug conjugates in cancer